{"filing":{"accession_number":"0001628280-26-058864","cik":"0001232524","ticker":"JAZZ","company_name":"Jazz Pharmaceuticals plc","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-25","primary_document":"jazz-20260825.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1232524/000162828026058864/jazz-20260825.htm"},"events":[{"id":29464,"run_id":26982,"accession_number":"0001628280-26-058864","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Jazz Pharmaceuticals announced FDA approval of two Ziihera-containing regimens for first-line treatment of HER2+ gastroesophageal adenocarcinoma, representing a significant regulatory and commercial milestone for the company's oncology pipeline. This is a material operational/product event—the approval of a new indication for an existing drug with demonstrated clinical benefit (26.4-month median OS, the longest reported in Phase 3 trials in this setting) that expands the addressable market and establishes a new standard of care. While not a traditional earnings release, M\u0026A, or financial obligation, this regulatory approval materially affects the company's business prospects and product portfolio.","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31758,"accession_number":"0001628280-26-058864","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Jazz Pharmaceuticals announced FDA approval of two Ziihera-containing regimens for first-line treatment of HER2+ gastroesophageal adenocarcinoma, representing a significant regulatory and commercial milestone for the company's oncology pipeline. This is a material operational/product event—the approval of a new indication for an existing drug with demonstrated clinical benefit (26.4-month median OS, the longest reported in Phase 3 trials in this setting) that expands the addressable market and establishes a new standard of care. While not a traditional earnings release, M\u0026A, or financial obligation, this regulatory approval materially affects the company's business prospects and product portfolio.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:11:47.162380+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31758,"accession_number":"0001628280-26-058864","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Jazz Pharmaceuticals announced FDA approval of two Ziihera-containing regimens for first-line treatment of HER2+ gastroesophageal adenocarcinoma, representing a significant regulatory and commercial milestone for the company's oncology pipeline. This is a material operational/product event—the approval of a new indication for an existing drug with demonstrated clinical benefit (26.4-month median OS, the longest reported in Phase 3 trials in this setting) that expands the addressable market and establishes a new standard of care. While not a traditional earnings release, M\u0026A, or financial obligation, this regulatory approval materially affects the company's business prospects and product portfolio.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:11:47.162380+00:00","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-08-25"}]}